ValueQ4, 24TTMSelling/general/admin expenses——Research & development——Operating income——Non-Operating Income, Total——Interest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses——Unusual income/expense——Pretax income——Equity in earnings——Taxes——Non-controlling/minority interest——After tax other income/expense——Net income before discontinued operations——Discontinued operations——Net income——Dilution adjustment——Preferred dividends——Diluted net income available to common stockholders——Basic earnings per share (Basic EPS)——Diluted earnings per share (Diluted EPS)——Average basic shares outstanding——Diluted shares outstanding——EBITDA——EBIT——Cost of revenue——Other cost of goods sold——Depreciation & amortization (cash flow)——
Molecular Partners AG - American Depositary Shares
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.